Novarel Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to expansion of fertility treatment clinics, established clinical use of hCG therapies, increasing infertility diagnosis rates, availability of injectable hormone formulations, growth of reproductive endocrinology practices.

The growth in the forecast period can be attributed to increasing adoption of advanced fertility treatments, rising maternal age trends, expansion of personalized fertility protocols, growing investments in reproductive health services, increasing demand for outpatient fertility therapies. Major trends in the forecast period include increasing demand for fertility hormone therapies, growing use of injectable gonadotropins, expansion of assisted reproductive treatments, rising focus on hormone monitoring protocols, enhanced clinical customization of fertility care.

The rising prevalence of infertility is expected to drive the growth of the Novarel market in the future. Infertility refers to the inability to conceive after one year of regular, unprotected sexual intercourse or the inability to carry a pregnancy to full term. The increasing global infertility rates are leading to higher demand for fertility treatments, especially ovulation induction with hCG (such as Novarel), as women seek solutions for ovulation difficulties. Novarel helps treat infertility by stimulating ovulation in women who have trouble releasing eggs and supporting sperm production in men with low testosterone levels, thereby improving the chances of conception. For example, in April 2023, the World Health Organization (WHO) reported that approximately 17.5% of the adult population globally, or roughly 1 in 6 people, experience infertility. Therefore, the growing prevalence of infertility is driving the demand for Novarel.

Rising healthcare spending is expected to drive the growth of the Novarel market in the future. This increase in healthcare spending is influenced by factors such as the growing prevalence of chronic diseases, an aging population, and advancements in medical technologies. Rising healthcare investment supports Novarel by improving access to effective infertility treatments, including the use of human chorionic gonadotropin (hCG), which stimulates ovulation and enhances fertility outcomes. This leads to more efficient and targeted care in reproductive medicine. For example, in May 2024, the Office for National Statistics, a UK-based government agency, reported that total healthcare spending rose by 5.6% in nominal terms from 2022 to 2023, marking a notable acceleration compared to the 0.9% increase in 2022. As a result, the rising healthcare spending is contributing to the growth of the Novarel market.

The rising number of drug approvals is also expected to contribute to the growth of the Novarel market. Drug approvals refer to the process by which regulatory authorities, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), review and authorize a new drug for sale and use. The increasing number of drug approvals is fueled by advancements in technology, greater investment in healthcare, streamlined regulatory processes, a focus on precision medicine, growing global demand for treatments, and the expansion of therapies for rare diseases. Approvals for Novarel confirm its efficacy and safety in treating infertility, ensuring its continued availability for clinical use. For example, in October 2024, ClinicalTrials.gov, a U.S.-based government clinical trials registry, reported that in 2023, 39,710 new studies were registered, bringing the cumulative total to 477,203 studies by the end of 2023, compared to 38,023 new studies in 2022, which resulted in a cumulative total of 437,493 studies by the end of 2022. As such, the rising number of drug approvals is helping to drive the growth of the Novarel market.

Major companies operating in the novarel market are Ferring Pharmaceuticals Inc.

North America was the largest region in the novarel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the novarel market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the novarel market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the novarel market by increasing costs of imported active hormone ingredients, sterile injectables, medical-grade packaging, and cold-chain logistics services. Fertility clinics in North America and Europe are most affected due to dependence on imported pharmaceutical inputs, while Asia-Pacific faces elevated export-related cost pressures. These tariffs are raising treatment costs and impacting patient affordability. However, they are also encouraging domestic hormone production, regional pharmaceutical manufacturing, and supply chain diversification within reproductive health markets.

The novarel market research report is one of a series of new reports that provides novarel market statistics, including novarel industry global market size, regional shares, competitors with a novarel market share, detailed novarel market segments, market trends and opportunities, and any further data you may need to thrive in the novarel industry. This novarel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Novarel is a brand name for a medication containing human chorionic gonadotropin (hCG), commonly used in fertility treatments. hCG is a hormone that plays a vital role in the reproductive system, particularly in regulating ovulation in women and stimulating testosterone production in men. Novarel is administered via injection, and its use is carefully monitored by healthcare professionals to ensure effectiveness and minimize potential side effects.

The primary indications for Novarel include ovulation induction, hypogonadotropic hypogonadism, and fertility preservation. Ovulation induction involves hormonal therapy to stimulate egg development and release, facilitating ovulation. Novarel is distributed through hospitals, pharmacies, and online pharmacies, and is used by various end users, including adults and geriatric patients.

The novarel market consists of sales of novarel (HCG) injection, novarel pre-filled kits, customized dosage forms, and supportive accessories. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.